Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)

Zvera investors saw shares fall roughly 24% after European regulators issued a negative CHMP opinion on arimoclomol. The investigation focuses on whether investors who suffered losses may have potential securities law claims tied to the July 24, 2026 selloff. NEW YORK, July 27, 2026...